|
Catalog #
|
Source:
|
Lot #
|
Size:
|
|
AP1248a
|
Rabbit
|
SH020712M
|
0.1 mg
|
|
Concentration:
|
Accession:
|
Clone Name:
|
Isotype:
|
|
0.25 mg/ml
|
NP_775298, O75928-2
|
RB0676
|
Rabbit Ig
|
|
Applications:
|
Reactivity:
|
MW (kDa):
|
|
WB, IHC, E
|
H
|
63396 Da
|
|
Target/Specificity:
|
|
This antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide unique to the C-terminal region of human PIASx1.
|
|
Other Names:
|
|
E3 SUMO-protein ligase PIAS2; Protein inhibitor of activated STAT2; Protein inhibitor of activated STAT x;; DAB2-interacting protein; DIP; Androgen receptor-interacting protein 3; ARIP3; PIAS-NY protein; PIAS2; PIASX; PIAS2-alpha; PIASx-alpha
|
|
Application Data:
|
Western blot analysis of PIASx1 polyclonal antibody (Cat. #AP1248a) with bacterial and HL-60 cell lysates. Lane A: endogenous PIASx1 in HL-60 cells; Lane B: bacteria expressing recombinant GST-PIASx1 fusion protein. PIASx1 was detected using purified Pab. Secondary HRP-anti-rabbit was used for signal visualization with chemiluminescence. |
Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma. |
|
|
Background:
|
|
PIASX functions as an E3-type small ubiquitin-like modifier (SUMO) ligase, stabilizing the interaction between UBE2I and the substrate, and as a SUMO-tethering factor. This protein plays a crucial role as a transcriptional coregulator in various cellular pathways, including the STAT pathway, the p53 pathway and the steroid hormone signaling pathway. The effects of this transcriptional coregulation, transactivation or silencing may vary depending upon the biological context and the PIAS2 isoform studied. However, it seems to be mostly involved in gene silencing. PIASX binds to sumoylated ELK1 and enhances its transcriptional activity by preventing recruitment of HDAC2 by ELK1, thus reversing SUMO-mediated repression of ELK1 transactivation activity. This antibody is directed against an epitope specific to PIAS2-alpha. Isoform PIAS2-beta, but not isoform PIAS2-alpha, promotes MDM2 sumoylation. Isoform PIAS2-alpha promotes PARK7 sumoylation. Isoform PIAS2-beta promotes NCOA2 sumoylation more efficiently than isoform PIAS2-alpha.
|
|
Background References:
|
- Arora, T., et al., J. Biol. Chem. 278(24):21327-21330 (2003).
- Wu, S., et al., Oncogene 22(3):351-360 (2003).
- Liu, B., et al., Proc. Natl. Acad. Sci. U.S.A. 95(18):10626-10631 (1998).
- Wu, L., et al., Mech. Dev. 65 (1-2), 3-17 (1997).
|
|
Product Citations:
|
- Jones, Marius C., et al. PNAS 2006 Oct 31;103(44):16272-16277. (Applications: WB)
|
|
Application Notes:
|
| The suggested dilution is: | |
| ELISA | 1:1,000 |
| Western blotting | 1:100~500 |
| Immunohistochemistry | 1:50~100 |
|
|
Format:
|
|
Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein G column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS.
|
|
Storage:
|
|
Maintain refrigerated at 2-8°C for up to 6 months. For long
term storage store at -20°C.
|
|
Precautions:
|
|
This product is for research use only. Not for use in diagnostic
or therapeutic procedures.
|
